Oppenheimer Assigns a Buy Rating on Syros Pharmaceuticals (SYRS)

Oppenheimer analyst Mark Breidenbach assigned a Buy rating to Syros Pharmaceuticals (SYRSResearch Report) today and set a price target of $13.00. The company’s shares closed last Tuesday at $9.30.

According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 22.8% and a 46.7% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Iovance Biotherapeutics.

Currently, the analyst consensus on Syros Pharmaceuticals is a Strong Buy with an average price target of $14.50, a 53.3% upside from current levels. In a report issued on March 5, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.65 and a one-year low of $4.26. Currently, Syros Pharmaceuticals has an average volume of 777.9K.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYRS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.